The study of doctors’ attitude to the use of fixed combinations in the therapy of arterial hypertension
DOI:
https://doi.org/10.24959/sphhcj.23.289Keywords:
arterial hypertension; antihypertensive drugs; fixed combinations; questionnaire survey; method of a priori ranking.Abstract
Aim. To study doctors’ attitude to the prescription of fixed combinations of antihypertensive drugs by a questionnaire survey, as well as the factors that determine this choice.
Materials and methods. Specially designed questionnaires were used for the study; the data were analyzed using the method of a priori ranking, system analysis, mathematical-statistical methods, the analogy and comparison methods.
Results. The questionnaire survey involved 162 doctors, among them cardiologists (45.1 % of the sample) with the work experience from 12 to 40 years dominated. The studies have shown that most doctors prefer to combine angiotensin-converting enzyme inhibitors with a diuretic or a calcium channel blocker. When prescribing fixed combinations, their effectiveness, safety and duration of action of the medicines selected are taken into account.
Conclusions. A sociological study has been conducted among doctors; the groups of combined antihypertensive drugs that are preferred have been identified. It has been found that for the further development of the pharmaceutical provision of the population, doctors see the need to develop new combined medicines. Therefore, according to the interviewed doctors, such combinations of drugs as ramipril with indapamide, bisoprolol with indapamide, metoprolol with ramipril and indapamide; ramipril with amlodipine and indapamide are the most relevant, safe and effective among the new drugs proposed for the development.
References
Al-Makki A., DiPette D., Whelton P. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2022. Vol. 79, No. 1. P. 293-301. DOI: 10.1161/HYPERTENSIONAHA.121.18192.
Шолойко Н. В., Гончар А. О. Порівняльний аналіз асортиментного переліку лікарських засобів для лікування артеріальної гіпертензії згідно з вітчизняними та міжнародними клінічними настановами. Фармац. журн. 2022. Т. 77, № 1. С. 31-39. DOI: https://doi.org/10.32352/0367-3057.1.22.03.
Rea F., Savaré L., Corrao G., Merlino L., Mancia G. Two-Drug Fixed-Dose combination as initial antihypertensive treatment strategy confers higher medication adherence compared to monotherapy. Journal of Hypertension. 2021. Vol. 39, No. 1. P. 43. DOI: 10.1097/01.Hjh.0000744812.30266.80.
Симоненко Н. А., Подгайна М. В., Немченко А. С., Шпичак О. С. Ретроспективний аналіз фармацевтичного ринку кардіологічних препаратів в Україні за 2016-2020 роки. Фармац. журн. 2021. Т. 76, № 3. С. 14-24. DOI: https://doi.org/10.32352/0367-3057.3.21.02.
20 International Society of Hypertension, Hypertension Clinical Practice Guidelines / T. Unger et al. Hypertension. 2020. Vol. 75, No. 6. URL: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15026.
Kishore S. P., Salam A., Rodgers A., Jaffe M. G., Frieden T. Fixed combinations for hypertension. The Lancet. 2018. Vol. 392, № 10150. P. 819-820. DOI: 10.1016/S0140-6736(18)31814-2.
Parati G., Kjeldsen S., Coca A., Cushman W., Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021. Vol. 77, No. 2. P. 692-705. DOI: 10.1161/HYPERTENSIONAHA.120.15781.
Демчук М. Б., Маланчук Н. В., Грошовий Т. А. Ретроспективне дослідження асортименту комбінованих антигіпертензивних лікарських препаратів в Україні за 2022 рік порівняно з 2015 роком. Фармац. журн. 2022. Т. 77, № 5. С. 12-22. DOI: 10.32352/0367-3057.5.22.02.
Математичне планування експерименту при проведенні наукових досліджень в фармації / Т. А. Грошовий та ін. Тернопіль : Укрмедкнига, 2008. 367 с.
Belay S., Goedert J., Woldesenbet A., Rokooei S. AHP based multi criteria decision analysis of success factors to enhance decision making in infrastructure construction projects. J. Cogent Engineering. 2022. Vol. 9, No. 1. P. 1985046-2156072. DOI: 10.1080/23311916.2022.2043996.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
